171 related articles for article (PubMed ID: 29362505)
1. Polypharmacy and adverse drug events among propensity score matched privately insured persons with and without spinal cord injury.
Hand BN; Krause JS; Simpson KN
Spinal Cord; 2018 Jun; 56(6):591-597. PubMed ID: 29362505
[TBL] [Abstract][Full Text] [Related]
2. Dose and Duration of Opioid Use in Propensity Score-Matched, Privately Insured Opioid Users With and Without Spinal Cord Injury.
Hand BN; Krause JS; Simpson KN
Arch Phys Med Rehabil; 2018 May; 99(5):855-861. PubMed ID: 29307814
[TBL] [Abstract][Full Text] [Related]
3. Adverse drug events in the outpatient setting: an 11-year national analysis.
Bourgeois FT; Shannon MW; Valim C; Mandl KD
Pharmacoepidemiol Drug Saf; 2010 Sep; 19(9):901-10. PubMed ID: 20623513
[TBL] [Abstract][Full Text] [Related]
4. Prescription drug claims following a traumatic spinal cord injury for older adults: a retrospective population-based study in Ontario, Canada.
Guilcher SJT; Hogan ME; Calzavara A; Hitzig SL; Patel T; Packer T; Lofters AK
Spinal Cord; 2018 Nov; 56(11):1059-1068. PubMed ID: 30065350
[TBL] [Abstract][Full Text] [Related]
5. Medication-related problems in individuals with spinal cord injury in a primary care-based clinic.
Patel T; Milligan J; Lee J
J Spinal Cord Med; 2017 Jan; 40(1):54-61. PubMed ID: 26446538
[TBL] [Abstract][Full Text] [Related]
6. Incidence of acute spinal cord injury and associated complications of methylprednisolone therapy: a national population-based study in South Korea.
Choi SH; Sung CH; Heo DR; Jeong SY; Kang CN
Spinal Cord; 2020 Feb; 58(2):232-237. PubMed ID: 31527724
[TBL] [Abstract][Full Text] [Related]
7. Health care resource utilization and medical costs of spinal cord injury with neuropathic pain in a commercially insured population in the United States.
Margolis JM; Juneau P; Sadosky A; Cappelleri JC; Bryce TN; Nieshoff EC
Arch Phys Med Rehabil; 2014 Dec; 95(12):2279-87. PubMed ID: 25159715
[TBL] [Abstract][Full Text] [Related]
8. Probable effects of polypharmacy and equivalent doses of psychotropic drugs on prevalence of adverse drug events among psychiatric inpatients in a general hospital in Japan.
Aoyama K; Tachi T; Kubo S; Koyama A; Watanabe M; Aoyama S; Noguchi Y; Tanaka K; Yasuda M; Shibata A; Mizui T; Teramachi H
Hum Psychopharmacol; 2024 May; 39(3):e2890. PubMed ID: 38180732
[TBL] [Abstract][Full Text] [Related]
9. Is the number of prescribing physicians an independent risk factor for adverse drug events in an elderly outpatient population?
Green JL; Hawley JN; Rask KJ
Am J Geriatr Pharmacother; 2007 Mar; 5(1):31-9. PubMed ID: 17608245
[TBL] [Abstract][Full Text] [Related]
10. Adverse drug event nonrecognition in emergency departments: an exploratory study on factors related to patients and drugs.
Roulet L; Ballereau F; Hardouin JB; Chiffoleau A; Potel G; Asseray N
J Emerg Med; 2014 Jun; 46(6):857-64. PubMed ID: 24565882
[TBL] [Abstract][Full Text] [Related]
11. Medication profile and polypharmacy in adults with pediatric-onset spinal cord injury.
Hwang M; Zebracki K; Vogel LC
Spinal Cord; 2015 Sep; 53(9):673-8. PubMed ID: 25896344
[TBL] [Abstract][Full Text] [Related]
12. Adverse drug events in hospitalized elderly.
Gray SL; Sager M; Lestico MR; Jalaluddin M
J Gerontol A Biol Sci Med Sci; 1998 Jan; 53(1):M59-63. PubMed ID: 9467435
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for hospital admissions associated with adverse drug events.
Kongkaew C; Hann M; Mandal J; Williams SD; Metcalfe D; Noyce PR; Ashcroft DM
Pharmacotherapy; 2013 Aug; 33(8):827-37. PubMed ID: 23686895
[TBL] [Abstract][Full Text] [Related]
14. Use of a Bioinformatics-Based Toxicity Scoring System to Assess Serotonin Burden and Predict Population-Level Adverse Drug Events from Concomitant Serotonergic Drug Therapy.
Culbertson VL; Rahman SE; Bosen GC; Caylor ML; Xu D
Pharmacotherapy; 2019 Feb; 39(2):171-181. PubMed ID: 30620414
[TBL] [Abstract][Full Text] [Related]
15. Risk factors associated with adverse drug events among older adults in emergency department.
Chen YC; Fan JS; Chen MH; Hsu TF; Huang HH; Cheng KW; Yen DH; Huang CI; Chen LK; Yang CC
Eur J Intern Med; 2014 Jan; 25(1):49-55. PubMed ID: 24200546
[TBL] [Abstract][Full Text] [Related]
16. Increased risk of acute pancreatitis in persons with spinal cord injury: a population-based, propensity score-matched longitudinal follow-up study.
Ho WT; Yeh KC; Pan SL
Spinal Cord; 2021 Nov; 59(11):1170-1176. PubMed ID: 34075206
[TBL] [Abstract][Full Text] [Related]
17. The risks of polypharmacy following spinal cord injury.
Kitzman P; Cecil D; Kolpek JH
J Spinal Cord Med; 2017 Mar; 40(2):147-153. PubMed ID: 24970339
[TBL] [Abstract][Full Text] [Related]
18. Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation.
Martinez BK; Baker WL; Sood NA; Bunz TJ; Meinecke AK; Eriksson D; Coleman CI
Pharmacotherapy; 2019 Feb; 39(2):196-203. PubMed ID: 30597611
[TBL] [Abstract][Full Text] [Related]
19. Multimorbidity, polypharmacy, referrals, and adverse drug events: are we doing things well?
Calderón-Larrañaga A; Poblador-Plou B; González-Rubio F; Gimeno-Feliu LA; Abad-Díez JM; Prados-Torres A
Br J Gen Pract; 2012 Dec; 62(605):e821-6. PubMed ID: 23211262
[TBL] [Abstract][Full Text] [Related]
20. Characterization and preventability of adverse drug events as cause of emergency department visits: a prospective 1-year observational study.
Lo Giudice I; Mocciaro E; Giardina C; Barbieri MA; Cicala G; Gioffrè-Florio M; Carpinteri G; Di Grande A; Spina E; Arcoraci V; Cutroneo PM
BMC Pharmacol Toxicol; 2019 Apr; 20(1):21. PubMed ID: 31029178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
